Technical Analysis for ABOS - Acumen Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 2.34 -1.27% -0.03
ABOS closed down 0.84 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction -1.27%
NR7 Range Contraction -1.27%
NR7-2 Range Contraction -1.27%
Lower Bollinger Band Walk Weakness -1.27%
Wide Bands Range Expansion -1.27%
Oversold Stochastic Weakness -1.27%
Calm After Storm Range Contraction -2.09%
NR7 Range Contraction -2.09%
Lower Bollinger Band Walk Weakness -2.09%
Wide Bands Range Expansion -2.09%

   Recent Intraday Alerts

Alert Time
Down 5% about 2 hours ago
Down 3% about 2 hours ago
60 Minute Opening Range Breakdown about 2 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 2 % about 4 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Treatment Of Alzheimer's Amyloid Beta Targeted Immunotherapy

Is ABOS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.09
52 Week Low 2.08
Average Volume 192,794
200-Day Moving Average 3.06
50-Day Moving Average 2.61
20-Day Moving Average 2.81
10-Day Moving Average 2.69
Average True Range 0.22
RSI (14) 40.12
ADX 26.84
+DI 19.17
-DI 24.60
Chandelier Exit (Long, 3 ATRs) 2.70
Chandelier Exit (Short, 3 ATRs) 2.89
Upper Bollinger Bands 3.42
Lower Bollinger Band 2.21
Percent B (%b) 0.13
BandWidth 42.95
MACD Line -0.07
MACD Signal Line 0.02
MACD Histogram -0.0928
Fundamentals Value
Market Cap 137.25 Million
Num Shares 57.9 Million
EPS -1.11
Price-to-Earnings (P/E) Ratio -2.14
Price-to-Sales 538.78
Price-to-Book 0.62
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.57
Resistance 3 (R3) 2.57 2.51 2.53
Resistance 2 (R2) 2.51 2.46 2.51 2.52
Resistance 1 (R1) 2.44 2.43 2.41 2.44 2.51
Pivot Point 2.38 2.38 2.37 2.38 2.38
Support 1 (S1) 2.31 2.33 2.28 2.31 2.23
Support 2 (S2) 2.25 2.30 2.25 2.22
Support 3 (S3) 2.18 2.25 2.21
Support 4 (S4) 2.18